BioArchitec Group Ltd. | SANO AI Organoid Precision Medicine

Turnaround Time

7–10 Days

From biopsy sample to clinical drug sensitivity report

Primary Organoids

P0 / 1

Direct primary organoids avoiding genetic passaging drift

High-Throughput

>200

Drug & concentration panels screened simultaneously

Precision Modeling

IC₅₀

AI-calculated drug inhibition response curves

IP & Backing

>13M

Government R&D Grants & 13+ Innovation Patents

SANO: Precision at Scale. Blueprint for Life.

AI-Driven Microfluidic
Organoid Screening

The SANO platform automates patient-derived organoid (PDO) micro-isolation, sorting, drug dispensing, and viability tracking. By eliminating human manual bias and long passaging times, SANO yields reliable IC₅₀ sensitivity profiles in 7–10 days directly from primary tissue.

Zero Passaging Drift: Tests directly on primary P0/1 tumor organoids, maintaining genomic and phenotypic fidelity.

AI Vision & Sorting: Automated Computer Vision algorithms select uniform organoid micro-geometry and isolate viable clusters.

High-Throughput Assay: Evaluates chemotherapy, targeted inhibitors, and immunotherapies across >200 parallel drug conditions.

Request SANO platform PDF

SANO Platform Ecosystem

AI Computer Vision

SANO AI Core

Real-time morphologic scoring & IC₅₀ curve calculation

Microfluidic Chip

SANO-MC Chip

High-density organoid arraying & drug incubation

TISSUE DIGESTION KIT

TDK-10 Kit

Gentle primary tumor tissue dissociation

Culture Media

PDOM Medium

Formulated for rapid primary P0/1 expansion

Compliant with FDA Modernization Act 3.0 (NAMs) | Align with 15th Five-Year Plan for Economic and Social Development

Standard Operating Procedure

Automated Experiment Workflow

Standardized pipeline from primary patient biopsy tissue to high-precision IC₅₀ drug response reporting.

Product Catalogue

BioArchitec Ecosystem

One-stop solution for organoid automation, 3D cellular research and tissue generation.

Organoid Platform

SANO Platform

AI Organoid Drug Sensitivity Platform

Automated high-throughput platform integrating AI microfluidics and sorting to deliver standardized IC₅₀ patient drug sensitivity reports in 7–10 days.

P0/1 primary tissue organoids without passaging
Screen >200 drug/concentration panels
AI-enabled viability scoring and reporting

3D Biofabrication

MAPS-2 Workstation

3D Biofabrication Workstation

Autonomous 24/7 3D bioprinting and liquid handling system with integrated "Vitality Chamber" and HEPA13 filtration for cleanroom-free bio-printing.

Integrated HEPA13 Vitality Chamber
Cloud-based 3D tissue model library
Multi-material bioprinting & dispensing

3D Bioprinter

MAPS-1+ Bioprinter

Multi-Material Bioprinting System

Advanced three-head bio-printing system with 1 µm axial accuracy and auto-calibration for high-precision, multi-material tissue models.

Axial accuracy: 1 µm precision
3 independent dynamic pressure printheads
Sealed anti-contamination chamber

Microfluidic Chip

µCell Spheroid Chip

High-Density Culture Chip

Generates 2,400 uniform cell clusters simultaneously with low-attachment surface and high optical clarity for fluorescence assays.

2,400 uniform cluster micro-wells
High optical transparency for imaging
Drug response and metabolic gradient assays

Culture Reagent

PDOM Culture Medium

PDO Expansion Formula (100 mL)

Formulated for primary expansion of patient-derived tumor organoids, ensuring maximum success rates while preserving genomic fidelity.

High P0/1 organoid success rate
Preserves genomic & phenotypic fidelity
Formulations for CRC, HCC, and SCLC

Tissue digestion

TDK-10 Dissociation Kit

Tissue Dissociation Kit

Gentle enzymatic dissociation blend designed to breakdown primary tumor resections and biopsies into high-yield viable cell clusters.

Gentle blend preserves cellular markers
Optimized cluster yield for micro-organoid culture
Standardized 30-minute protocol

Clinical & Industry Impact

Applications

Empowering personalized oncology therapy decision-making and accelerating pharmaceutical drug discovery.

Precision Oncology & Companion Diagnostics

Cancer patients face critical time constraints during treatment planning. SANO enables oncologists to test >200 chemotherapy, targeted, and combination drug regimens in 7–10 days directly on biopsy samples—preventing ineffective toxicities and guiding effective treatments.

Colorectal Cancer (CRC) Small Cell Lung Cancer (SCLC) Hepatocellular Carcinoma (HCC)

Pharma Preclinical CRO & Drug Discovery

Accelerate hit-to-lead selection and pharmacodynamic profiling. By replacing animal models with high-throughput primary human organoid screens, SANO reduces early phase clinical trial failure rates and aligns with FDA Modernization Act 3.0 guidelines.

High-Throughput Screening In-Vitro Toxicity Profiling Combination Therapy Testing

Clinical Pharmacology R&D

Conduct comprehensive in-vitro evaluations of drug candidates using patient-derived organoids to ensure safety and determine precise therapeutic windows prior to clinical trials.

In-vitro safety profiling Dosage threshold identification Off-target effect analysis Species-specific accuracy

BioArchitec Group Ltd.

Creating the Blueprint for Life

Vision: Creating the blueprint for life through cutting-edge biotechnologies. Mission: Leading precision medicine, benefiting patients with technology.

>13M

Government Funding

HK Innovation & Tech Commission + HKSTP

13+

Invention Patents

Proprietary microfluidics, robotics, and AI algorithms

10+

Research Collaborations

Global research institutes & university hospital networks

GBA N+

HK R&D + GBA Integration

Integrated development in GBA